Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsAntimicrobial Stewardship

ICU · Antimicrobial Stewardship

Acute severe community-acquired pneumonia: antimicrobial de-escalation and stewardship

Also known as Antibiotic stewardship in CAP · Procalcitonin-guided therapy · De-escalation in pneumonia

Antimicrobial de-escalation is narrowing or stopping antibiotics based on culture results and clinical response. For severe CAP: start broad (a beta-lactam plus a macrolide, or a respiratory fluoroquinolone), then narrow at 48-72h based on: (1) culture results (sputum, blood, urinary antigens), (2) clinical response (improving fever, WBC, oxygenation, inflammatory markers), (3) procalcitonin trend. Procalcitonin-guided algorithm (Christ-Crain 2006 bands): antibiotics strongly discouraged under 0.1 ng/mL, discouraged under 0.25 ng/mL, encouraged over 0.25 ng/mL, strongly encouraged over 0.5 ng/mL; stop with clinical improvement. Duration: randomised trials support 3-day and 5-day minimum courses in clinically stable CAP (el Moussaoui 2006; Uranga 2016). Stewardship principles: right drug, right dose, right duration, right route. Avoid: unnecessary broadening, prolonged courses, duplicate coverage.

low19 referencesUpdated 20 Aug 202619 min readVerification in progress

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Do NOT continue broad-spectrum antibiotics beyond 72h without reviewing cultures
  • Procalcitonin-guided stopping (under 0.25 ng/mL with clinical improvement) is proven safe in multiple randomised trials
  • De-escalation is NOT dangerous — stewardship meta-analysis links it to BETTER outcomes
  • Five days is sufficient for most clinically stable CAP — longer only for specific organisms and undrained complications
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Do NOT continue broad-spectrum antibiotics beyond 72h without reviewing cultures
  • Procalcitonin-guided stopping (under 0.25 ng/mL with clinical improvement) is proven safe in multiple randomised trials
  • De-escalation is NOT dangerous — stewardship meta-analysis links it to BETTER outcomes
  • Five days is sufficient for most clinically stable CAP — longer only for specific organisms and undrained complications
The one-line answer

De-escalation is the whole game in severe CAP. Start broad — a beta-lactam plus a macrolide, or a respiratory fluoroquinolone — then narrow at 48 to 72 hours on the cultures, the clinical response, and the procalcitonin trend. In the original adult CAP algorithm, antibiotics were discouraged below 0.25 ng/mL and strongly encouraged above 0.5 ng/mL. Randomised trials show five-day courses suffice once the patient is clinically stable, and procalcitonin-guided stopping safely shortens courses without raising mortality or relapse.[16][9][5]

Meet the patient

Mr K is sixty-four and three days into a severe pneumococcal CAP that put him in septic shock. You loaded ceftriaxone and azithromycin within the hour, drew blood cultures and urinary antigens, and he has been climbing out of it for two days.[1]

It is now hour seventy-two. Both blood cultures grow penicillin-sensitive Streptococcus pneumoniae, the Legionella urinary antigen is negative, he has been afebrile for a day, and the procalcitonin that peaked at 3.8 has fallen to 0.4. The ward-round question — and the exam question — is the same: what do you narrow to, what do you stop, and when is the whole course done? Hold that decision and every section below falls into place.[1]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References19ShowHide
  1. [1]Niederman MS, Torres A Severe community-acquired pneumonia Eur Respir Rev, 2022.PMID 36517046
  2. [2]Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited BMC Med, 2017.PMID 28114931
  3. [3]Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial Lancet, 2010.PMID 20097417
  4. [4]Schuetz P, Christ-Crain M, Wolbers M, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial JAMA, 2009.PMID 19738090
  5. [5]Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis Lancet Infect Dis, 2018.PMID 29037960
  6. [6]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Am J Respir Crit Care Med, 2019.PMID 31573350
  7. [7]Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection N Engl J Med, 2018.PMID 29781385
  8. [8]el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study BMJ, 2006.PMID 16763247
  9. [9]Uranga A, España PP, Bilbao A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial JAMA Intern Med, 2016.PMID 27455166
  10. [10]Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med, 2006.PMID 16625125
  11. [11]Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam Clin Infect Dis, 2017.PMID 27940946
  12. [12]Schuts EC, Hulscher ME, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis Lancet Infect Dis, 2016.PMID 26947617
  13. [13]De la Calle C, Ternavasio-de la Vega HG, Morata L, et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis J Infect, 2018.PMID 29360520
  14. [14]Parente DM, Cunha CB, Mylonakis E, Timbrook TT The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications Clin Infect Dis, 2018.PMID 29340593
  15. [15]Póvoa P, Coelho L, Dal-Pizzol F, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians Intensive Care Med, 2023.PMID 36592205
  16. [16]Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial Am J Respir Crit Care Med, 2006.PMID 16603606
  17. [17]Carratalà J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial Arch Intern Med, 2012.PMID 22732747
  18. [18]Athanassa Z, Makris G, Dimopoulos G, Falagas ME Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis Drugs, 2008.PMID 19016574
  19. [19]Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection Lancet, 1993.PMID 8094770

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousVTE Prophylaxis & Treatment — LMWH, IPC, Thrombolysis & the ICU DefaultHaematology / coagulationNextAcute severe community-acquired pneumonia: infection control in ICUAntimicrobial Stewardship